These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

855 related articles for article (PubMed ID: 28710745)

  • 41. Targeting GLI1 Suppresses Cell Growth and Enhances Chemosensitivity in CD34+ Enriched Acute Myeloid Leukemia Progenitor Cells.
    Long B; Wang LX; Zheng FM; Lai SP; Xu DR; Hu Y; Lin DJ; Zhang XZ; Dong L; Long ZJ; Tong XZ; Liu Q
    Cell Physiol Biochem; 2016; 38(4):1288-302. PubMed ID: 27008269
    [TBL] [Abstract][Full Text] [Related]  

  • 42. The Multi-kinase Inhibitor Debio 0617B Reduces Maintenance and Self-renewal of Primary Human AML CD34
    Murone M; Radpour R; Attinger A; Chessex AV; Huguenin AL; Schürch CM; Banz Y; Sengupta S; Aguet M; Rigotti S; Bachhav Y; Massière F; Ramachandra M; McAllister A; Riether C
    Mol Cancer Ther; 2017 Aug; 16(8):1497-1510. PubMed ID: 28468777
    [TBL] [Abstract][Full Text] [Related]  

  • 43. MiR-29b/Sp1/FUT4 axis modulates the malignancy of leukemia stem cells by regulating fucosylation via Wnt/β-catenin pathway in acute myeloid leukemia.
    Liu B; Ma H; Liu Q; Xiao Y; Pan S; Zhou H; Jia L
    J Exp Clin Cancer Res; 2019 May; 38(1):200. PubMed ID: 31097000
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Delineation of target expression profiles in CD34+/CD38- and CD34+/CD38+ stem and progenitor cells in AML and CML.
    Herrmann H; Sadovnik I; Eisenwort G; Rülicke T; Blatt K; Herndlhofer S; Willmann M; Stefanzl G; Baumgartner S; Greiner G; Schulenburg A; Mueller N; Rabitsch W; Bilban M; Hoermann G; Streubel B; Vallera DA; Sperr WR; Valent P
    Blood Adv; 2020 Oct; 4(20):5118-5132. PubMed ID: 33085758
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Inhibition of mitochondria induces apoptosis and reduces telomere length and activity in acute myeloid leukemia stem cells.
    Valipour B; Davari S; Farahzadi R; Pourrasol S; Mehran N; Dizaji Asl K; Altaha SM; Hojjati Z; Nozad Charoudeh H
    Cell Biochem Funct; 2023 Dec; 41(8):1477-1487. PubMed ID: 38014526
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Long term maintenance of myeloid leukemic stem cells cultured with unrelated human mesenchymal stromal cells.
    Ito S; Barrett AJ; Dutra A; Pak E; Miner S; Keyvanfar K; Hensel NF; Rezvani K; Muranski P; Liu P; Larochelle A; Melenhorst JJ
    Stem Cell Res; 2015 Jan; 14(1):95-104. PubMed ID: 25535865
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Stem cell factor as a survival and growth factor in human normal and malignant hematopoiesis.
    Hassan HT; Zander A
    Acta Haematol; 1996; 95(3-4):257-62. PubMed ID: 8677752
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Pre-apoptotic response to therapeutic DNA damage involves protein modulation of Mcl-1, Hdm2 and Flt3 in acute myeloid leukemia cells.
    Wergeland L; Sjøholt G; Haaland I; Hovland R; Bruserud Ø; Gjertsen BT
    Mol Cancer; 2007 May; 6():33. PubMed ID: 17498302
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Ex vivo expansion of normal progenitor cells from acute myeloid leukemia cell-contaminated CD34+ peripheral blood progenitor cells after mafosfamide purging.
    Stilz R; Grünebach F; Bader P; Vogel W; Kanz L; Brugger W; Scheding S
    J Hematother Stem Cell Res; 2001 Dec; 10(6):777-85. PubMed ID: 11798504
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Cardiac glycoside ouabain efficiently targets leukemic stem cell apoptotic machinery independent of cell differentiation status.
    Poohadsuan J; O'Doherty GA; Owattanapanich W; Kungwankiattichai S; Rojanasakul Y; Issaragrisil S; Luanpitpong S
    Cell Commun Signal; 2023 Oct; 21(1):283. PubMed ID: 37828578
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Targeting AMPK-ULK1-mediated autophagy for combating BET inhibitor resistance in acute myeloid leukemia stem cells.
    Jang JE; Eom JI; Jeung HK; Cheong JW; Lee JY; Kim JS; Min YH
    Autophagy; 2017 Apr; 13(4):761-762. PubMed ID: 28118076
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Impact of Leukemia Stem Cells Phenotype Expression on Response to Induction Therapy in Acute Myeloid Leukemia Patients.
    Almohsen F; Al-Mudallal SS
    Cardiovasc Hematol Disord Drug Targets; 2020; 20(2):145-151. PubMed ID: 31438833
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Abivertinib synergistically strengthens the anti-leukemia activity of venetoclax in acute myeloid leukemia in a BTK-dependent manner.
    Huang S; Li C; Zhang X; Pan J; Li F; Lv Y; Huang J; Ling Q; Ye W; Mao S; Huang X; Jin J
    Mol Oncol; 2020 Oct; 14(10):2560-2573. PubMed ID: 32519423
    [TBL] [Abstract][Full Text] [Related]  

  • 54. IL1RAP-specific T cell engager depletes acute myeloid leukemia stem cells.
    Zhang Y; Park M; Ghoda LY; Zhao D; Valerio M; Nafie E; Gonzalez A; Ly K; Parcutela B; Choi H; Gong X; Chen F; Harada K; Chen Z; Nguyen LXT; Pichiorri F; Chen J; Song J; Forman SJ; Amanam I; Zhang B; Jin J; Williams JC; Marcucci G
    J Hematol Oncol; 2024 Aug; 17(1):67. PubMed ID: 39143574
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Cytotoxicity Assessment and Apoptosis-related Gene Profiling of Antibody Treated Acute Myeloid Leukemia (AML) and Acute Lymphocytic Leukemia (ALL) Cancerous Cell Lines.
    Habibi-Anbouhi M; Kafi Z; Ghazizadeh L; Kharazi S; Behdani M; Faraji F; Shokrgozar MA
    Iran J Allergy Asthma Immunol; 2019 Oct; 18(6):679-687. PubMed ID: 32245312
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Cotargeting BCL-2 and PI3K Induces BAX-Dependent Mitochondrial Apoptosis in AML Cells.
    Rahmani M; Nkwocha J; Hawkins E; Pei X; Parker RE; Kmieciak M; Leverson JD; Sampath D; Ferreira-Gonzalez A; Grant S
    Cancer Res; 2018 Jun; 78(11):3075-3086. PubMed ID: 29559471
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Shutting Down Acute Myeloid Leukemia and Myelodysplastic Syndrome with BCL-2 Family Protein Inhibition.
    Sharma P; Pollyea DA
    Curr Hematol Malig Rep; 2018 Aug; 13(4):256-264. PubMed ID: 29982865
    [TBL] [Abstract][Full Text] [Related]  

  • 58. The natural alkaloid Jerantinine B has activity in acute myeloid leukemia cells through a mechanism involving c-Jun.
    Alhuthali HM; Bradshaw TD; Lim KH; Kam TS; Seedhouse CH
    BMC Cancer; 2020 Jul; 20(1):629. PubMed ID: 32635894
    [TBL] [Abstract][Full Text] [Related]  

  • 59. CD34⁺/CD38⁻ acute myelogenous leukemia cells aberrantly express Aurora kinase A.
    Yang J; Ikezoe T; Nishioka C; Nobumoto A; Udaka K; Yokoyama A
    Int J Cancer; 2013 Dec; 133(11):2706-19. PubMed ID: 23686525
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Antileukemia Efficacy and Mechanisms of Action of SL-101, a Novel Anti-CD123 Antibody Conjugate, in Acute Myeloid Leukemia.
    Han L; Jorgensen JL; Brooks C; Shi C; Zhang Q; Nogueras González GM; Cavazos A; Pan R; Mu H; Wang SA; Zhou J; Ai-Atrash G; Ciurea SO; Rettig M; DiPersio JF; Cortes J; Huang X; Kantarjian HM; Andreeff M; Ravandi F; Konopleva M
    Clin Cancer Res; 2017 Jul; 23(13):3385-3395. PubMed ID: 28096272
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 43.